Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.
PRNewswire - November 12, 2001
"Omega interferon is a natural human interferon produced by genetic engineering technologies," said BioMedicines' Chief Medical Officer, Dr. Peter Langecker. "Results from these two independent studies provide evidence for an antiviral effect against all HCV genotypes (1, 2, 3, and 4). Despite occasional symptoms typically associated with interferon treatment, patients appeared to tolerate omega interferon quite well. As a result, we were able to continue raising the dose level, producing progressive anti-hepatitis C effects."
The European study was undertaken to evaluate the safety, tolerability and antiviral activity of six different dose levels of omega interferon in previously untreated patients with chronic hepatitis C. In this open-label study patients were treated for 3-12 months. All major HCV genotypes were present. Antiviral activity was assessed by measuring blood levels of HCV RNA and by liver enzyme testing. The interim results show that omega interferon can reduce HCV to undetectable levels in interferon-naive patients having any of the four major HCV genotypes.
The U.S. study was designed to evaluate the effect of increasing dose levels of omega interferon in three groups of patients with genotype 1, hepatitis C infection that was completely resistant to prior treatment with alpha interferon given with or without a second antiviral drug. Resistance meant that HCV was always detectable in blood despite treatment with alpha interferon. Within 48 hours of the initiation of treatment with omega interferon, HCV RNA fell sharply in all patients, and in some to undetectable levels.
Chief Executive Officer Dr. Mark Moran said, "We are pleased with these results. We believe they also support our new drug delivery efforts with this drug. In collaboration with ALZA, we are also putting omega interferon into the implantable DUROS(R) delivery system. With DUROS(R), we hope to be able to deliver omega interferon for months with a single administration."
Hepatitis C infection can lead to severe impairment of liver function, liver fibrosis, and liver cancer. According to the U.S. Center for Disease Control, HCV infects nearly 3 million people in the United States, and the World Health Organization estimates 170 million people are infected worldwide. Many infected persons are unaware of the infection. The spread of HCV infection has reached epidemic proportions, as some experts believe that without substantial improvements in treatment, the death toll from HCV infection will surpass that from HIV.
About BioMedicines, Inc.
BioMedicines, Inc., a privately held pharmaceutical company, is developing first line therapies for the treatment of cancer and infectious diseases such as viral hepatitis. The company specializes in redirecting the development of drugs to new and more valuable indications. The company has current development and/or commercialization agreements with ALZA Corporation, Boehringer Ingelheim International GmbH, Schering AG, and G.D. Searle & Co. Additional information about BioMedicines, Inc. can be found on the World Wide Web at http://www.biomedicinesinc.com.
Contact:
BioMedicines, Inc. Noonan/Russo Communications, Inc.
Mark Moran, Chief Executive Officer Emily Katz
(510) 814-0112 (415) 677-4455, ext. 282
e-mail: mark.moran@biomedicinesinc.com e-mail: e.katz@noonanrusso.com
SOURCE BioMedicines, Inc.
Web Site: http://www.biomedicinesinc.com
011112
PR011121
Copyright © 2001 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.PRNewswire.com.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .